Australia markets closed

SAB Biotherapeutics, Inc. (SABS)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
4.0300-0.0200 (-0.49%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 37.18M
Enterprise value -13.48M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.65
Enterprise value/revenue -3.43
Enterprise value/EBITDA 0.35

Trading information

Stock price history

Beta (5Y monthly) 0.80
52-week change 3-58.98%
S&P500 52-week change 322.38%
52-week high 310.5000
52-week low 34.0000
50-day moving average 34.6833
200-day moving average 36.6942

Share statistics

Avg vol (3-month) 313.32k
Avg vol (10-day) 32.58k
Shares outstanding 59.23M
Implied shares outstanding 69.23M
Float 85.93M
% held by insiders 119.13%
% held by institutions 138.41%
Shares short (15 Apr 2024) 425.62k
Short ratio (15 Apr 2024) 42.2
Short % of float (15 Apr 2024) 40.37%
Short % of shares outstanding (15 Apr 2024) 40.28%
Shares short (prior month 15 Mar 2024) 420.89k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:10
Last split date 305 Jan 2024

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-6,187.90%

Management effectiveness

Return on assets (ttm)-35.29%
Return on equity (ttm)-95.51%

Income statement

Revenue (ttm)2.24M
Revenue per share (ttm)0.41
Quarterly revenue growth (yoy)-85.90%
Gross profit (ttm)N/A
EBITDA -34.42M
Net income avi to common (ttm)-42.19M
Diluted EPS (ttm)-7.6400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)56.57M
Total cash per share (mrq)6.13
Total debt (mrq)5.91M
Total debt/equity (mrq)10.31%
Current ratio (mrq)5.45
Book value per share (mrq)6.21

Cash flow statement

Operating cash flow (ttm)-25.12M
Levered free cash flow (ttm)-17.95M